Chimeric Antigen Receptor (CAR) T cell therapy is a revolutionary approach in the field of cancer immunotherapy.
Reframing the Inherent Donor Supply Chain Ecosystem to Support the Imminent CGT Manufacturing Boom: Recap of the Allogeneic Cell Therapies Summit 2023
Key takeaways from AllCells’ VP of Donor Operations presentation on reframing the donor supply chain ecosystem to support the CGT manufacturing boom.
The World’s Largest Apheresis Network Serves as a Catalyst to Advance Cell and Gene Therapies
AllCells and Discovery continue to expand their solutions alongside the CGT industry to help researchers overcome roadblocks.
Cancer Immunotherapy: An increasing emphasis on CD4+ T cells and MHC Class II Neoantigens
QuickSwitch™ Class II Tetramer Peptide Exchange and Quantitation Kit utilises a patented technique for exchanging up to ten peptides on an MHC Class II Tetramer.
A Deep Dive into the Hidden Power of Programmed Cell Death: Unlocking Therapeutic Potential with Antibodies
ProSci has 25+ years of expertise in developing antibodies. This white paper details use of ProSci antibodies in the study of programmed cell death.
LAG-3 – Major Histocompatibility Complex (MHC) – T Cell Receptor (TCR) Pathway
Dual inhibition of LAG-3 and other checkpoint pathways may synergistically increase T cell antitumour activity.
Is your drug candidate able to reverse the T Cell Exhaustion-like state in MBL’s in vitro functional screening assay?
The process of T cell exhaustion & how it can be harnessed for immuno-oncology drug discovery and for immune checkpoint screening of drug candidates.
Human Cord Blood and Primary Cells
Caltag Medsystems are the European distributor of StemExpress, a leading supplier of human cord blood and cord blood primary cells. Currently, there are over 200 clinical trials worldwide investigating the use of cord blood stem cells in regenerative therapy. Cord
Peripheral Blood Mononuclear Cells: A Brief Review
Peripheral blood mononuclear cells (PBMCs) are a diverse mixture of highly specialized immune cells that play key roles in keeping our bodies healthy. This brief review tells a short story about PBMCs starting with their origin, the different immune cells
The Dark Side of CAR-T Therapy – Cytokine Release Syndrome (Diaclone)
Immunotherapies such as monoclonal antibodies, bispecific antibodies (Bi-specific T-cell engagers or BiTEs) and adoptive T-cell therapies (e.g. CAR-modified T-cell) have provided great advances in cancer treatment. However, testing new therapies is not without risk. The most common and potentially severe